vs

Side-by-side financial comparison of Seadrill Ltd (SDRL) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Seadrill Ltd is the larger business by last-quarter revenue ($273.0M vs $151.7M, roughly 1.8× Tarsus Pharmaceuticals, Inc.). Seadrill Ltd runs the higher net margin — -3.7% vs -5.5%, a 1.9% gap on every dollar of revenue. Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -8.9%).

Seadrill is an offshore drilling contractor providing worldwide offshore drilling services to the oil and gas industry. Its primary business is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deep water in both benign and harsh environments. It provides a contract-based service and primarily serves the oil super-majors, integrated oil and gas, state-owned national oil, and independent oil and gas companies.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

SDRL vs TARS — Head-to-Head

Bigger by revenue
SDRL
SDRL
1.8× larger
SDRL
$273.0M
$151.7M
TARS
Higher net margin
SDRL
SDRL
1.9% more per $
SDRL
-3.7%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-8.9%
SDRL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SDRL
SDRL
TARS
TARS
Revenue
$273.0M
$151.7M
Net Profit
$-10.0M
$-8.4M
Gross Margin
Operating Margin
-1.1%
-5.3%
Net Margin
-3.7%
-5.5%
Revenue YoY
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SDRL
SDRL
TARS
TARS
Q4 25
$273.0M
$151.7M
Q3 25
$280.0M
$118.7M
Q2 25
$288.0M
$102.7M
Q1 25
$248.0M
$78.3M
Q4 24
$66.4M
Q3 24
$263.0M
$48.1M
Q2 24
$267.0M
$40.8M
Q1 24
$275.0M
$27.6M
Net Profit
SDRL
SDRL
TARS
TARS
Q4 25
$-10.0M
$-8.4M
Q3 25
$-11.0M
$-12.6M
Q2 25
$-42.0M
$-20.3M
Q1 25
$-14.0M
$-25.1M
Q4 24
$-23.1M
Q3 24
$32.0M
$-23.4M
Q2 24
$253.0M
$-33.3M
Q1 24
$60.0M
$-35.7M
Operating Margin
SDRL
SDRL
TARS
TARS
Q4 25
-1.1%
-5.3%
Q3 25
9.3%
-12.2%
Q2 25
2.1%
-21.6%
Q1 25
7.3%
-33.5%
Q4 24
-36.8%
Q3 24
17.9%
-52.3%
Q2 24
-81.6%
Q1 24
29.1%
-136.5%
Net Margin
SDRL
SDRL
TARS
TARS
Q4 25
-3.7%
-5.5%
Q3 25
-3.9%
-10.6%
Q2 25
-14.6%
-19.8%
Q1 25
-5.6%
-32.1%
Q4 24
-34.8%
Q3 24
12.2%
-48.7%
Q2 24
94.8%
-81.6%
Q1 24
21.8%
-129.4%
EPS (diluted)
SDRL
SDRL
TARS
TARS
Q4 25
$-0.17
Q3 25
$-0.17
$-0.30
Q2 25
$-0.68
$-0.48
Q1 25
$-0.23
$-0.64
Q4 24
$-0.57
Q3 24
$0.49
$-0.61
Q2 24
$3.49
$-0.88
Q1 24
$0.81
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SDRL
SDRL
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$339.0M
$417.3M
Total DebtLower is stronger
$613.0M
$72.4M
Stockholders' EquityBook value
$2.9B
$343.4M
Total Assets
$3.9B
$562.2M
Debt / EquityLower = less leverage
0.21×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SDRL
SDRL
TARS
TARS
Q4 25
$339.0M
$417.3M
Q3 25
$402.0M
$401.8M
Q2 25
$393.0M
$381.1M
Q1 25
$404.0M
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$835.0M
$323.6M
Q1 24
$298.5M
Total Debt
SDRL
SDRL
TARS
TARS
Q4 25
$613.0M
$72.4M
Q3 25
$612.0M
$72.3M
Q2 25
$612.0M
$72.1M
Q1 25
$611.0M
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$609.0M
$71.6M
Q1 24
$29.9M
Stockholders' Equity
SDRL
SDRL
TARS
TARS
Q4 25
$2.9B
$343.4M
Q3 25
$2.9B
$335.1M
Q2 25
$2.9B
$332.6M
Q1 25
$2.9B
$342.5M
Q4 24
$224.5M
Q3 24
$2.9B
$237.5M
Q2 24
$3.1B
$252.2M
Q1 24
$2.9B
$275.2M
Total Assets
SDRL
SDRL
TARS
TARS
Q4 25
$3.9B
$562.2M
Q3 25
$4.1B
$534.6M
Q2 25
$4.1B
$495.0M
Q1 25
$4.1B
$500.8M
Q4 24
$377.0M
Q3 24
$376.3M
Q2 24
$4.3B
$376.8M
Q1 24
$349.3M
Debt / Equity
SDRL
SDRL
TARS
TARS
Q4 25
0.21×
0.21×
Q3 25
0.21×
0.22×
Q2 25
0.21×
0.22×
Q1 25
0.21×
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.20×
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SDRL
SDRL
TARS
TARS
Operating Cash FlowLast quarter
$-40.0M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SDRL
SDRL
TARS
TARS
Q4 25
$-40.0M
$19.3M
Q3 25
$28.0M
$18.3M
Q2 25
$11.0M
$-29.4M
Q1 25
$-27.0M
$-20.7M
Q4 24
$-22.2M
Q3 24
$-27.0M
$-8.7M
Q2 24
$79.0M
$-14.4M
Q1 24
$29.0M
$-37.8M
Free Cash Flow
SDRL
SDRL
TARS
TARS
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
SDRL
SDRL
TARS
TARS
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
SDRL
SDRL
TARS
TARS
Q4 25
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%
Cash Conversion
SDRL
SDRL
TARS
TARS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-0.84×
Q2 24
0.31×
Q1 24
0.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons